Key Developments: Cumberland Pharmaceuticals Inc (CPIX.O)
5.04USD
18 Jun 2013
$0.00 (+0.00%)
$5.04
$5.09
$5.15
$5.00
45,851
63,380
$6.85
$4.03
Latest Key Developments (Source: Significant Developments)
Cumberland Pharmaceuticals Inc And PT. SOHO Industri Pharmasi Enter Into Exclusive Licensing Agreement For Caldolor In Indonesia
Cumberland Pharmaceuticals Inc announced it has entered into an exclusive agreement with Indonesia's PT.SOHO IndustriPharmasi(a SOHO Group company) for the registration and commercialization of Caldolor (ibuprofen) Injection, which is used to treat pain and fever in the hospital setting. Under the terms of the agreement, SOHO receives an exclusive license to Caldolor for the Indonesian market. SOHO will be responsible for seeking regulatory approval, ongoing regulatory reporting, product marketing, distribution and sales in the territory following approval. Cumberland maintains responsibility for the intellectual property, product formulation, manufacturing and other supported activities. In exchange for the license to the product, Cumberland will receive upfront and milestone licensing payments, as well as transfer prices on future sales of the drug. Full Article
Cumberland Pharmaceuticals Inc Reaffirms FY 2012 Guidance
Cumberland Pharmaceuticals Inc announced that it has achieved another quarter of steady financial results and remains on track to hit fiscal 2012 guidance. Full Article
Cumberland Pharmaceuticals Inc's Caldolor Reduces Narcotic Doses In Pediatric Pain Patients
Cumberland Pharmaceuticals Inc announced top-line results from a clinical pediatric pain study evaluating the safety and analgesic efficacy of Caldolor (ibuprofen) Injection in treating pain in tonsillectomy patients ranging from 6 to 16 years old. When administered prior to surgery, Caldolor use was associated with a statistically significant reduction in the number of post-operative narcotic doses required in patients in the efficacy evaluable population. There were also consistent trends toward reduction in pain scores and the incidence of nausea and vomiting in patients receiving Caldolor. Importantly, no safety concerns were observed during this study. The study, in combination with the ongoing work to evaluate the treatment of fever in children, will be used to pursue a pediatric indication for Caldolor. Full Article
Cumberland Pharmaceuticals Inc Reaffirms FY 2012 EPS Guidance-Conference Call
Cumberland Pharmaceuticals Inc announced that for fiscal 2012, it remain comfortable and on track to hit guidance for earnings per share (EPS) of $0.32 to $0.36. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report EPS of $0.34 for fiscal 2012. Full Article
Cumberland Pharmaceuticals Inc Reaffirms FY 2011 Revenue Guidance
Cumberland Pharmaceuticals Inc announced that it is reaffirming its fiscal 2011 revenue guidance of $51-$55 million. According to I/BE/S Estimates, analysts on an average are expecting the Company to report revenue of $52 million for fiscal 2011. Full Article
Cumberland Pharmaceuticals Inc Appoints Rick S. Greene Chief Financial Officer
Cumberland Pharmaceuticals Inc announced that Rick S. Greene, a financial advisor to the Company, has been appointed Chief Financial Officer (CFO), effective October 18, 2011. He has served as Interim Vice President, Finance & Accounting since April of this year. Full Article
Cumberland Pharmaceuticals Inc Raises FY 2011 Revenue Guidance
Cumberland Pharmaceuticals Inc raised its fiscal 2011 revenue guidance to be in the range of $51-$55 million. According to I/B/E/S Estimates, analysts were expecting the Company to report revenues of $51 million for fiscal 2011. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
